Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).
Giovanni Scambia(Agostino Gemelli University Polyclinic), Domenica Lorusso(Agostino Gemelli University Polyclinic), Grazia Artioli(Ospedale di Mirano), Nicoletta Colombo(University of Milano-Bicocca), Anna Maria Mosconi(Azienda Ospedaliera di Perugia), Germana Tognon(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Enrico Breda(Fatebenefratelli Hospital), Stefano Tamberi(Ospedale per gli Infermi), Cláudia Casanova, Filippo Greco(University of Catania), Chiara Cassani(University of Pavia), Serafina Mammoliti(Ospedale Policlinico San Martino), Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giorgio Valabrega(CTO Hospital), Carmen Pisano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Raspagliesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Rita Ceccherini(University of Trieste), Giorgia Mangili(Vita-Salute San Raffaele University)
Cited by 6
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k